Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

Vittorio Gebbia, De Petris, Vittorio Gebbia, Filippo De Marinis

Risultato della ricerca: Articlepeer review

16 Citazioni (Scopus)

Abstract

Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.
Lingua originaleEnglish
pagine (da-a)116-122
Numero di pagine7
RivistaAnnals of Oncology
Volume16
Stato di pubblicazionePublished - 2005

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Entra nei temi di ricerca di 'Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer'. Insieme formano una fingerprint unica.

Cita questo